FDA notifications.  Lamivudine/zidovudine combination approved for pediatric use.
D002648:Child; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D004338:Drug Combinations; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage / Q000627:therapeutic use*; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration; D015215:Zidovudine / Q000008:administration & dosage / Q000627:therapeutic use*
D004338:Drug Combinations; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine; D015215:Zidovudine